KR20220075329A - 알콜성 간염의 치료 - Google Patents

알콜성 간염의 치료 Download PDF

Info

Publication number
KR20220075329A
KR20220075329A KR1020227010063A KR20227010063A KR20220075329A KR 20220075329 A KR20220075329 A KR 20220075329A KR 1020227010063 A KR1020227010063 A KR 1020227010063A KR 20227010063 A KR20227010063 A KR 20227010063A KR 20220075329 A KR20220075329 A KR 20220075329A
Authority
KR
South Korea
Prior art keywords
25hc3s
salt
dose
days
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227010063A
Other languages
English (en)
Korean (ko)
Inventor
웨이치 린
제임스 이 브라운
테렌스 블라쉬케
Original Assignee
듀렉트 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀렉트 코퍼레이션 filed Critical 듀렉트 코퍼레이션
Publication of KR20220075329A publication Critical patent/KR20220075329A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227010063A 2019-09-30 2020-09-29 알콜성 간염의 치료 Pending KR20220075329A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US62/908,465 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US62/933,206 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US63/060,564 2020-08-03
US202063081208P 2020-09-21 2020-09-21
US63/081,208 2020-09-21
PCT/US2020/053315 WO2021067297A1 (en) 2019-09-30 2020-09-29 Treatment of alcoholic hepatitis

Publications (1)

Publication Number Publication Date
KR20220075329A true KR20220075329A (ko) 2022-06-08

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227010063A Pending KR20220075329A (ko) 2019-09-30 2020-09-29 알콜성 간염의 치료

Country Status (13)

Country Link
US (2) US20220378802A1 (https=)
EP (1) EP4037650A4 (https=)
JP (1) JP7830313B2 (https=)
KR (1) KR20220075329A (https=)
CN (2) CN119868374A (https=)
AU (1) AU2020357818A1 (https=)
BR (1) BR112022005039A2 (https=)
CA (1) CA3155422A1 (https=)
IL (1) IL291287A (https=)
MX (1) MX2022003778A (https=)
PH (1) PH12022550698A1 (https=)
TW (1) TW202128184A (https=)
WO (1) WO2021067297A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4359420A4 (en) * 2021-06-25 2025-07-16 Durect Corp 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) * 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US20150072962A1 (en) * 2012-04-12 2015-03-12 Virgini Commonwealth University Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
HRP20220112T1 (hr) * 2013-12-24 2022-04-15 Virginia Commonwealth University Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3493810A4 (en) * 2016-08-02 2020-04-08 Durect Corporation COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE

Also Published As

Publication number Publication date
JP7830313B2 (ja) 2026-03-16
TW202128184A (zh) 2021-08-01
CA3155422A1 (en) 2021-04-08
BR112022005039A2 (pt) 2022-06-21
AU2020357818A1 (en) 2022-04-14
US20220378802A1 (en) 2022-12-01
CN119868374A (zh) 2025-04-25
PH12022550698A1 (en) 2023-04-03
JP2022549621A (ja) 2022-11-28
CN114555044B (zh) 2025-02-14
CN114555044A (zh) 2022-05-27
EP4037650A4 (en) 2023-10-18
EP4037650A1 (en) 2022-08-10
MX2022003778A (es) 2022-04-25
IL291287A (en) 2022-05-01
WO2021067297A1 (en) 2021-04-08
US20260102410A1 (en) 2026-04-16

Similar Documents

Publication Publication Date Title
US20260102410A1 (en) Treatment of Alcoholic Hepatitis
Phatak et al. A phase 1/2, dose‐escalation trial of deferasirox for the treatment of iron overload in HFE‐related hereditary hemochromatosis
Jewell et al. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial
AU2013259526B2 (en) New methods
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
Ware et al. Evaluation and treatment of transfusional iron overload in children
JP5555425B2 (ja) 薬剤復元または希釈のための塩化ナトリウム溶液
CN107088225A (zh) 治疗法布里病的给药方案
EP4706756A2 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
JP2012102110A (ja) 造影剤の注入を受けるヒトの処置方法
JP2010248242A (ja) ヒト腎臓疾患の診断
Galle et al. Comparison of the effects of pioglitazone versus placebo when given in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis: results from the PIOren Study
WO2021237146A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
JP2022526914A5 (https=)
HK40073572A (en) Treatment of alcoholic hepatitis
BR122025021620A2 (pt) Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica
HK40073572B (zh) 酒精性肝炎的治疗
JP2022538210A (ja) 腎機能障害患者における高アンモニア血症の治療
AU2021273936A1 (en) Treatment of non-alcoholic steatohepatitis (NASH)
Dupon et al. Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients
WO2025101669A1 (en) Treatment of alcohol-associated hepatitis
WO2026026911A1 (zh) 一种二肽衍生物的应用
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
Twisk et al. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 2 diabetes mellitus 3

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application